Jevtana Related Published Studies
Well-designed clinical trials related to Jevtana (Cabazitaxel)
TROPIC: Phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer. [2011.04]
Other research related to Jevtana (Cabazitaxel)
Managing side effects of the novel taxane cabazitaxel in castrate-resistant
prostate cancer. [2012]
The European Medicines Agency review of cabazitaxel (Jevtana®) for the treatment
of hormone-refractory metastatic prostate cancer: summary of the scientific
assessment of the committee for medicinal products for human use. [2012]
Cabazitaxel: a novel microtubule inhibitor. [2011.07.09]
A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: a phase I/II study. [2011.05]
Cabazitaxel for the treatment of prostate cancer. [2011.04]
Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer. [2011.03.10]
Cabazitaxel: filling one of the gaps in the treatment of prostate cancer. [2011.01.12]
Cabazitaxel for the treatment of castration-resistant prostate cancer. [2011.01]
Critical appraisal of cabazitaxel in the management of advanced prostate cancer. [2010.12.03]
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. [2010.10.02]
Cabazitaxel, a new taxane with favorable properties. [2010.10]
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant
prostate cancer progressing after docetaxel treatment: a randomised open-label
trial. [2010]
Other possibly related research studies
[New drugs at the horizon for men with prostate cancer] [2010.05.26]
Castration-resistant prostate cancer: current and emerging treatment strategies. [2010.05.28]
Overcoming chemotherapy resistance in prostate cancer. [2011.06.15]
New options for the management of castration-resistant prostate cancer: a case perspective. [2011.02]
Current clinical trials in castrate-resistant prostate cancer. [2011.06]
Contemporary management of metastatic castration-resistant prostate cancer. [2011.05]
[Castration resistant prostate cancer 2011]. [2011.03]
Role of second-line systemic treatment post-docetaxel in metastatic castrate resistant prostate cancer- current strategies and future directions. [2011.03]
Optimal management of bone metastases in prostate cancer. [2011.06]
A renaissance in the medical treatment of advanced prostate cancer. [2010.12]
Improving outcomes with recent advances in chemotherapy for castrate-resistant prostate cancer. [2010.12.01]
Horizon scanning for novel therapeutics for the treatment of prostate cancer. [2010.12]
New and emerging agents for the treatment of castration-resistant prostate cancer. [2011.11]
Biomarkers in the Management and Treatment of Men with Metastatic Castration-Resistant Prostate Cancer. [2011.11.12]
Management Options in Advanced Prostate Cancer: What is the Role for Sipuleucel-T? [2011]
Novel therapeutics for the management of castration-resistant prostate cancer (CRPC). [2011.10.28]
New treatment options for patients with metastatic castration-resistant prostate cancer. [2011.09.22]
Second-line therapy for castrate-resistant prostate cancer: a literature review. [2011.09]
Chemotherapy-based treatment for castration-resistant prostate cancer. [2011.09.20]
Evolving therapeutic paradigms for advanced prostate cancer. [2011.05]
Translating scientific advancement into clinical benefit for castration-resistant prostate cancer patients. [2011.06.15]
Updates on therapeutic targets and agents in castration-resistant prostate cancer. [2011.06]
Broadening horizons in medical management of prostate cancer. [2011.06]
Current paradigms and Evolving concepts in metastatic castration-resistant prostate cancer. [2011.09]
New therapies for castration-resistant prostate cancer: efficacy and safety. [2011.08]
Pathways of chemotherapy resistance in castration-resistant prostate cancer. [2011.07.04]
Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space. [2011.04.23]
Current treatment strategies for castration-resistant prostate cancer. [2011.03]
Current and emerging treatment modalities for metastatic castration-resistant prostate cancer. [2011.04]
EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. [2011.04]
Novel agents and new therapeutics in castration-resistant prostate cancer. [2011.05]
[Actualities in prostate cancer in ASCO annual meeting 2010]. [2010.12]
Management of metastatic castration-resistant prostate cancer: recent advances. [2012]
Chemotherapy-based treatment for castration-resistant prostate cancer. [2011]
Pharmacotherapeutic management of locally advanced prostate cancer: current
status. [2011]
Evolving standards in the treatment of docetaxel-refractory castration-resistant
prostate cancer. [2011]
Current clinical trials in castrate-resistant prostate cancer. [2011]
|
